[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"open-angle-glaucoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:open-angle-glaucoma":151},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,44,82,105,140,162,186,207,232,263,287,316,344,365,386,406,439],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100535000","comparative-effectiveness-and-safety-of-elios-in-patients-with-open-angle-glaucoma-undergoing-cataract-surgery-100535000",false,"NCT06246136","Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery","A Prospective, Multicenter, Randomized Clinical Trial to Evaluate the Safety and Effectiveness of ELIOS vs Competitor in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery","Inclusion Criteria:\n\n1. Male or female subjects.\n2. 40 years old or older.\n3. Diagnosis of mild to moderate primary open-angle glaucoma, pseudoexfoliation glaucoma or pigmentary glaucoma:\n4. Visually significant cataract eligible for phacoemulsification.\n\nExclusion Criteria:\n\n1. All forms of angle closure glaucoma\n2. Secondary glaucoma, including traumatic, neovascular, uveitic, lens-induced, steroid-induced, angle-recession, glaucoma associated with vascular disorders, and glaucoma associated with increased episcleral venous pressure\n3. Congenital or developmental glaucoma\n4. Prior incisional glaucoma surgery, intraocular surgery or ocular laser treatment of any type with the exception of selective laser trabeculoplasty (SLT) occurring a minimum of 6 months prior to the Screening visit","ALL","40 Years",{"count":19,"type":20},194,"ESTIMATED","INTERVENTIONAL",[23],"NA","The primary study objective is to compare the effectiveness of the combination of phacoemulsification with intraocular lens implant with ELIOS or competitor device in reducing IOP at 12 months postoperatively.",[26],"Open Angle Glaucoma",[28,29,30],"Excimer Laser","Micro-bypass","Trabeculostomy","RECRUITING","2026-06-15",{"date":34,"type":35},"2026-06-17","ACTUAL",{"date":37,"type":35},"2023-12-05",{"date":39,"type":20},"2028-12",{"name":41,"class":42},"Elios Vision, Inc.","INDUSTRY",16,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100640261","phase-1-topical-insulin-for-glaucoma-ting2-100640261","NCT07619482","Topical Insulin for Glaucoma (TING2)","A Phase 1\u002F2 Dose Escalation Followed by a Masked, Randomized, Placebo-Controlled Study to Evaluate Topical Insulin for Neuroprotection in Open Angle Glaucoma","Limited Inclusion Criteria - All Groups:\n\n* Provide written informed consent approved by the appropriate ethics committee\n* Age 18 years or older\n* Understand study procedures and have the ability and willingness to abide by all procedures during the study\n* Capable of providing informed consent\n* Diagnosis of glaucoma\n* Only one eye per patient will be selected as the study eye; if both eyes meet inclusion criteria, the eye with worse visual acuity and\u002For visual field will be selected\n\nLimited Exclusion Criteria - All Groups:\n\n* Pregnant or breastfeeding\n* Presence of any ocular pathology other than glaucoma that contributes to severe vision loss (retinopathy, maculopathy, severe uveitis, keratopathy, etc.)\n* Diagnosis of glucose intolerance, type 1 or type 2 diabetes mellitus\n* Inability to perform reliable visual field testing\n* Unable to provide informed consent\n* Unable to complete the tests and follow-ups required by the study","18 Years","90 Years",{"count":54,"type":20},90,[56,57],"PHASE1","PHASE2","This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1\u002F2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-free eye drops and delivered once daily. The primary objective is to determine the safety profile of topical insulin; secondary objectives assess effects on retinal structure, visual field, visual acuity, contrast sensitivity, and quality of life.",[26,60,61,62,63],"Primary Open Angle Glaucoma","Low Tension Glaucoma","Pigmentary Glaucoma","Pseudoexfoliation Glaucoma",[65,66,67,68,69],"glaucoma","neuroprotection","topical insulin","retinal ganglion cell","EYED-002","NOT_YET_RECRUITING","2026-05-26",{"date":73,"type":35},"2026-06-02",{"date":75,"type":20},"2026-06",{"date":77,"type":20},"2029-10",{"name":79,"class":80},"Stanford University","OTHER",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":81},"100617947","phase-4-24-hour-effect-of-rocklatan-compared-with-latanoprost-in-open-angle-glaucoma-and-ocular-hypertension-patients-100617947","NCT07325240","24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients","24-hour Effect Of Rocklatan Compared With Latanoprost In Open Angle Glaucoma And Ocular Hypertension Patients","Inclusion Criteria\n\n* Diagnosis of OHT or mild-to-moderate OAG in both eyes (OAG in one eye and OHT in the fellow eye is acceptable) based on VF, OCT and dilated fundus examination within one year of the screening visit.\n* Both eyes must qualify for the study with an IOP of ≥18 mmHg but ≤34 mmHg on history or at the screening visit\n* Be able and willing to provide signed informed consent and follow study instructions\n* Ability to cooperate with the examinations required for the study and be able to attend all study visits\n* If a contact lens wearer, willing to remove contact lenses at least 24 hours prior to each of the study visits.\n* Best-corrected visual acuity (BCVA) using ETDRS chart of +0.4 logMAR units (Snellen equivalent \\~ 20\u002F50) or better in each eye\n\nExclusion Criteria\n\nOcular:\n\n* Subjects with narrow angles (3 quadrants with Grade 2 or less according to Shaffer Scale), angle closure or a history of angle closure, or peripheral iridotomy in either eye\n* Severe glaucomatous damage\n* Difference in IOP between eyes \\> 4 mmHg (unmedicated) at any baseline time point\n* Use of more than two ocular hypotensive medications within 30 days of screening\n* Chronic or recurrent inflammatory eye diseases in either eye\n* Ocular infection or ocular inflammation in the past 3 months in either eye\n* Ocular trauma other than corneal abrasion within the past 6 months in either eye\n* Clinically significant retinal disease (e.g., severe diabetic retinopathy, exudative or severe non-exudative macular degeneration, macular edema, retinal vein or artery occlusion) in either eye\n* Cornea pathologic changes preventing reliable measurement (e.g., scarring, opacity, edema, keratoconus) in either eye\n* Myopia greater than -6.00D, or hyperopia greater than +2.00D in either eye\n* Central corneal thickness less than 480 μm or greater than 620 μm in either eye\n* Previous intraocular surgery other than routine uncomplicated cataract surgery in either eye\n* Previous glaucoma intraocular surgery or glaucoma laser procedures (except SLT performed more than 6 months ago) in either eye\n* Unilateral intraocular surgery or glaucoma laser procedures\n* Previous corneal refractive surgery in either eye (eg, radial keratotomy, PRK, LASIK, corneal cross-linking, etc.)\n* Severe dry eye in either eye\n* Use of ocular medications in either eye within 30 days of screening, with the exception of IOP-lowering medications (which must be washed out according to the provided schedule), and lubricating drops for dry eye (which may be used throughout the study)\n* Known hypersensitivity to any component of the formulation (eg, benzalkonium chloride, etc.), or to topical anesthetic\n\nSystemic:\n\n* Clinically significant systemic diseases which might interfere with the study\n* Participation in any interventional study within 30 days prior to screening visit\n* Changes of systemic medication that could have an effect on IOP within 30 days prior to screening, or anticipated during the study including, β-adrenergic antagonists, α-adrenergic agonists and antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers\n* Recent change in medications that are known to affect IOP within 30 days prior to the screening visit and during the study including: systemic\u002Finhaled steroids, calcium channel blockers, diuretics, and vasodilators\n* Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative pregnancy test result at the screening examination and must not intend to become pregnant during the study\n* Subjects with a known hypersensitivity or contraindications to any of the ingredients in the study medications",{"count":90,"type":20},30,[92],"PHASE4","The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG) or ocular hypertension (OHT).",[26,95],"Ocular Hypertension","2026-04-27",{"date":98,"type":35},"2026-05-01",{"date":100,"type":35},"2025-11-21",{"date":102,"type":20},"2027-10",{"name":104,"class":80},"Mayo Clinic",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":122,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":81},"100616257","quality-of-life-after-glaucoma-surgery-evaluating-the-patient-perspective-across-surgical-options-100616257","NCT07303257","Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options","Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options - G-SCOPE (Glaucoma Surgery - Comparative Patient Evaluation)","G-SCOPE","Inclusion Criteria:\n\n* Patient aged ≥ 18 years with an indication for glaucoma surgical treatment\n* Eligible surgical procedures: Preserflo™ MicroShunt with mitomycin C, Trabeculectomy with mitomycin C or non-penetrating deep sclerectomy with mitomycin C\n* Unilateral or bilateral glaucoma, open-angle or angle-closure, at early, moderate, or advanced stages\n* Pseudoxexfoliative or pigmentary glaucoma\n* Secondary glaucoma, including: uveitic glaucoma, Steroid-induced glaucoma, traumatic glaucoma\n* Written informed consent obtained prior to study participation\n\nExclusion Criteria:\n\n* Congenital glaucoma\n* Refractory glaucoma with a history of multiple previous surgeries\n* Ophthalmologic surgery within 6 months prior to inclusion\n* Severe visual co-morbidities (age-related macular degeneration, severe diabetic retinopathy, retinal degeneration, or similar conditions)\n* Expected difficulty with follow-up including poor anticipated compliance, planned travel or prolonged absence during the follow-up period\n* Illiteracy, inability to speak French or impaired cognitive capacity preventing adequate understanding of the study\n* Patients with a significant pre-existing impairment in quality of life attributable to a progressive physical illness or a neuropsychiatric disorder.\n* Patients under curatorship or guardianship\n* Pregnant women",{"count":114,"type":20},132,"OBSERVATIONAL","Glaucoma surgery currently relies on a wide therapeutic arsenal, ranging from conventional filtering surgeries to minimally invasive glaucoma surgery (MIGS). These techniques offer distinct efficacy and safety profiles, allowing tailored management across a broad spectrum of patients. Traditionally, surgical success has been evaluated using objective clinical outcomes, such as intraocular pressure (IOP) reduction and decreased reliance on topical treatments.\n\nHowever, the shift toward patient-centered medicine now requires consideration of the patient's perspective, including their subjective experience and the impact of treatment on quality of life. In this context, quality-of-life assessment has become a key component, promoting therapeutic alliance and patient adherence to care pathways. Despite its importance, few studies have evaluated and compared quality of life after glaucoma surgery using comparable surgical techniques.\n\nFurthermore, to our knowledge, no study has specifically assessed the independent effect of postoperative follow-up on quality of life after filtering surgery with a bleb. Given that postoperative management can be prolonged and demanding, it may significantly influence patients' perceptions of surgical outcomes and overall well-being.\n\nThis study aims to address these gaps by providing a more comprehensive evaluation of the impact of glaucoma surgery beyond traditional clinical outcomes. It may represent a first step toward the development of a more appropriate assessment tool that incorporates the realities of postoperative follow-up and the specific experiences of patients undergoing filtering surgery.\n\nThe study is based on the following hypotheses: filtering glaucoma surgery preserves patients' quality of life, with a stable NEI VFQ-25 score at six months postoperatively; postoperative quality of life may be influenced by the patient's postoperative care pathway; and quality-of-life scores remain correlated with objective clinical parameters, including intraocular pressure, visual acuity, medical treatment burden, and visual field damage.",[118,119,120,121,62],"Glaucoma Eye","Open-angle Glaucoma","Closed-Angle Glaucoma","Pseudo Exfoliative Syndrome",[123,124,125,126,127,128,129,130],"Glaucoma","Trabeculectomy","Sclerectomy","PreserFlo® Micro Shunt","Quality of life","Glaucome Surgery","MIGS","NEI-VFQ 25 (National Eye Institute- Visual Function Questionnaire 25)","2026-03-12",{"date":133,"type":35},"2026-03-16",{"date":135,"type":35},"2026-02-23",{"date":137,"type":20},"2027-08",{"name":139,"class":80},"Hospices Civils de Lyon",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":81},"100609676","phase-4-biomarkers-of-ocular-surface-damage-in-the-setting-of-topical-ocular-hypotensive-medication-use-100609676","NCT07217678","Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use","Inclusion Criteria:\n\n* Eye with open-angle glaucoma or suspected of open-angle glaucoma\n* Pseudophakic in eye of interest with Shafer grading ≥3\n* ≤ 3 daily applications of topical glaucoma medications for ≥6 months (of which one is a nightly preserved PGA)\n* Good adherence to medication regimen - screening questions to be asked of potential subject:\n* In the last month, what percentage of the time would you estimate missing the application of drops? (Must be ≤20%)\n* When was the last administration? (Last dose must have been within last 24 hours)\n* Presence of punctate epithelial erosions in the cornea (NEI scale \\> 3)\n\nExclusion Criteria:\n\n* Retinal disease (e.g., wet age-related macular degeneration, proliferative diabetic retinopathy, central retinal vein occlusion)\n* Use of topical or systemic immunosuppressor or immunomodulator drug (e.g., steroids, cyclosporine, lifitegrast, or antihistamines)\n* Use of preservative-free hypotensive medications\n* Any clinical contraindications to receiving intracameral bimatoprost implantation\n* History of recurrent conjunctivitis (e.g., allergic or atopic conjunctivitis)\n* History of partial or full corneal transplant\n* History of ophthalmic surgery (intraocular or tarsus-involving oculoplastic procedures) within last 6 months\n* History of subconjunctival glaucoma surgery (i.e., trabeculectomy, aqueous shunt, Xen implant) within last 6 months",{"count":147,"type":20},20,[92],"The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.",[123,151,95,152],"Open-Angle Glaucoma","Glaucoma Suspect","2026-03-03",{"date":155,"type":35},"2026-03-05",{"date":157,"type":35},"2026-02-09",{"date":159,"type":20},"2028-01-31",{"name":161,"class":80},"University of Miami",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":21,"phases":171,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":81},"100610487","phase-4-standalone-istent-infinite-and-idose-tr-for-management-of-moderate-to-severe-open-angle-glaucoma-100610487","NCT07228221","Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma","iStent Infinite and iDose TR for Management of Moderate to Severe Primary Open Angle Glaucoma Are a Safe and Effective Alternative to Filtering Surgery for IOP Reduction in Patients With Medically Uncontrolled Glaucoma. (POAG)","POAG","Inclusion Criteria:\n\n* Moderate to severe open angle glaucoma (including POAG, PG, and PXG)\n* Open angle configuration (Shaffer grade ≥ 3), normal angle anatomy9\n* Visual acuity HM or better\n* VF MD -6dB or worse\n* Failed medical therapy and\u002For laser treatment\n* Incisional glaucoma surgery contemplated as next intervention\n* Phakic or pseudophakic\n\nExclusion Criteria:\n\n* Traumatic, uveitic, neovascular glaucoma, or angle closure glaucoma\n* Previous incisional glaucoma surgery\n* ALT; History of iridotomy, SLT, or micropulse laser trabeculoplasty within the prior 90 days\n* Active ocular inflammation or edema, clinically significant corneal dystrophy\n* Corneal or other pathology preventing accurate Goldmann applanation tonometry",{"count":147,"type":20},[92],"The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.",[26,62,63],[168,175,176],"PG","PXG","2025-11-13",{"date":179,"type":35},"2025-11-14",{"date":181,"type":20},"2026-01-05",{"date":183,"type":20},"2031-12-31",{"name":185,"class":80},"Jonathon Myers",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":193,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":203,"leadSponsor":205,"locationsCount":81},"100583960","phase-4-efficacy-of-simbrinza-and-rocklatan-vs-cosopt-and-latanoprost-100583960","NCT06883123","Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","Efficacy and Tolerability of Simbrinza and Rocklatan vs. Cosopt","Inclusion criteria:\n\n* Adults aged Eighteen (18) years and older with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month. Evidence of optic nerve damage will be based on AAO Preferred Practice Patterns guidelines using either or both of the following:\n* Optic disc or retinal nerve fiber layer (RNFL) structural abnormalities\n* Diffuse or focal narrowing, or notching, of the optic disc rim, especially at the inferior or superior poles, which forms the basis for the ISNT rule\n* Progressive narrowing of the neuroretinal rim with an associated increase in cupping of the optic disc\n* Diffuse or localized abnormalities of the parapapillary RNFL, especially at the inferior or superior poles\n* Disc rim, parapapillary RNFL, or lamina cribrosa hemorrhages\n* Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue\n* Large extent of parapapillary atrophy\n* Reliable and reproducible visual field abnormality considered a valid representation of the subject's functional status\n* Visual field damage consistent with RNFL damage (e.g. nasal step, arcuate field defect, or paracentral depression in clusters of test sites)\n* Visual field loss across the horizontal midline in one hemifield that exceeds loss in the opposite hemifield (in early\u002F moderate cases)\n* Absence of other known explanations (e.g. optic disc drusen, optic nerve pit)\n* Mean diurnal IOP ≥ 18 mmHg and \\\u003C 28 mmHg at baseline in at least one eye with an inter-eye IOP difference \\\u003C 5 mmHg.\n* A central corneal thickness (CCT) within the range of 450-650 µm\n\nExclusion criteria:\n\n* Patients with prior ocular procedures or intraocular surgery within 1 year prior to baseline (e.g. cataract surgery).\n* Patients with prior history of glaucoma surgeries or laser treatment except patients with history of SLT \\>1 yr prior to baseline.\n* Contraindications or known hypersensitivity to any or all the study medications including Rocklatan, Simbrinza, Cosopt and Latanoprost or related class of drugs.\n* Patients with known history or presence of uncontrolled systemic diseases including diseases that, in investigator's opinion, may make it unsafe or undesirable for the subject to participate in the study and\u002F or limit adherence.\n* Patients with known history or presence of significant ocular diseases including corneal diseases, dystrophies or abnormalities that would prevent accurate IOP readings with GAT.\n* Patients with a history of uncontrolled IOP with the combination of either Rocklatan + Simbrinza or Cosopt + Latanoprost dual therapy.\n* Significant ocular surface findings (e.g. hyperemia, irritation) found during slit lamp examination that might affect the study.\n* Chronic use of any systemic medication for chronic diseases that may affect IOP.\n* Subjects who are pregnant, lactating or planning a pregnancy.\n* Any condition in the opinion in the investigator that would potentially confound the results of this study",true,{"count":195,"type":20},70,[92],"A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.",[26],"2025-05-14",{"date":201,"type":35},"2025-05-15",{"date":199,"type":35},{"date":204,"type":20},"2026-04-01",{"name":206,"class":80},"Prairie Eye Center",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":81},"100589356","efficacy-of-surgical-systems-in-combination-with-phacoemulsification-a-retrospective-analysis-100589356","NCT06953349","Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis","Real-World Efficacy of Hydrus Microstent With OMNI Surgical System in Combination With Phacoemulsification: a Retrospective Analysis","Inclusion Criteria:\n\n* Subjects with h\u002Fo CEIOL\u002FOMNI\u002FHydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data\n* have Glaucoma\n\nExclusion Criteria:\n\n* Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.\n* Patients with refractory CME or CME persisting 3 months or more post-operatively\n* Patients with incomplete IOP, medication logs or VF data within post-operative period\n* Prior incisional surgery or MIGS",{"count":215,"type":20},300,"Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis",[151],[219,220,221],"Hydrus Microstent","OMNI Surgical System","Phacoemulsification","2025-04-29",{"date":224,"type":35},"2025-05-01",{"date":226,"type":35},"2025-03-31",{"date":228,"type":20},"2025-12-31",{"name":230,"class":231},"Barnet Dulaney Perkins Eye Centers","NETWORK",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":242,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":258,"leadSponsor":260,"locationsCount":262},"100584168","vitamin-mix-b6-b9-b12-and-choline-for-glaucoma-patients-100584168","NCT06885827","Vitamin Mix (B6, B9, B12, And Choline) For Glaucoma Patients","Interventional Vitamin Mix Glaucoma Study (IVMGS) - A Prospective, Randomized, Two-Arm, Single-Center Study Protocol in Existing Glaucoma Patients.","IVMGS","Eligibility Criteria\n\nInclusion Criteria:\n\nPatients with the following characteristics will be eligible for inclusion in the trial:\n\n* 18 years or older at the time of inclusion\n* Diagnosis of Primary Open-Angle Glaucoma (POAG), Normal Tension-Glaucoma (NTG) or Pseudoexfoliation Glaucoma (PEXG) in one or both eyes diagnosticed by an ophthalmologist.\n* Best corrected Snellen VA of 0.3 or better in the study eye(s)\n* Two or more reliable VF tests with less than 15% false positives\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will be excluded from participation in the study:\n\n* Visual field damage worse than -16dB in the study eye(s)\n* Eye pressure greater than 35 mmHg in study eye(s) on either of two measurement occasions or a mean pressure of 30 mmHg over two occasions\n* Any disease affecting retinal function\n* Neurological or other non-glaucomatous conditions that may affect the visual field\n* Inability to perform visual field examination\n* Unwillingness to stop any intake of multivitamins or B vitamin substances\n* Known allergy or intolerance to B-vitamins\n* Previous eye surgery, except for uncomplicated cataract surgery\n* Pregnant or breastfeeding women\n* Women of childbearing potential who do not use reliable contraception\n* Any disease or condition likely to prevent long-term follow-up\n* Cancer diagnosis within the last 5 years (except treated squamous cell carcinoma)\n* History of liver disease or stomach ulcers\n* Inability to understand and speak Swedish or English",{"count":241,"type":20},80,[23],"This study aims to determine whether a combination of vitamins (B6, B9, B12, and choline) can help protect the eyes of people with glaucoma and slow vision loss. The study will assess whether these vitamins support retinal cells and maintain or improve their function.\n\nAdults aged 18 and older with primary open-angle glaucoma (including normal-tension glaucoma) or pseudoexfoliation glaucoma, and those with mild to moderate glaucoma, may be eligible. Participants must meet specific medical criteria and cannot take additional vitamin supplements during the study.\n\nParticipants will be randomly assigned to one of two groups: one group will take a daily vitamin supplement (B6, B9, B12, and choline) for one year, along with standard glaucoma care, while the other will continue standard care without extra vitamins. The vitamins used are well tolerated at selected doses, with possible mild side effects such as an upset stomach or tingling sensations. They will visit the clinic five times over 12 months (at the start, and at 3, 6, 9, and 12 months) for routine eye tests, including measuring eye pressure, checking vision and visual fields, taking scans of the eye's nerve layers (OCT), and completing an electroretinogram (ERG) to assess retinal function. Blood samples will also be collected.\n\nIf the vitamins are effective, this could provide an additional strategy alongside current eye pressure lowering treatments to reduce vision loss.",[119,63],[246,65,66,247,248,249,250,251,252,253,254],"methyl donor supplementation","randomized clinical trial","open-label","B6","B9","choline","visual field","optical coherence tomography","electroretinogram","2025-04-25",{"date":222,"type":35},{"date":226,"type":35},{"date":259,"type":20},"2027-03-31",{"name":261,"class":80},"Karolinska Institutet",2,{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":21,"phases":272,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":81},"100556334","trabeculopuncture-as-predictive-test-for-the-success-of-ab-interno-trabeculectomy-100556334","NCT06523751","Trabeculopuncture as Predictive Test for the Success of Ab Interno Trabeculectomy","Determining Distal Outflow Tract Function in Open Angle Glaucoma as a Predictive Test for the Success of Ab Interno Trabeculectomy","Inclusion Criteria:\n\n* individuals ≥ 18 years of age\n* clinical diagnosis of: primary open angle glaucoma, pigmentary glaucoma, or pseudoexfoliation glaucoma\n* uncontrolled intraocular pressure (IOP) with maximally tolerated medical therapy\n* progressive thinning of retinal nerve fiber layer assessed by Spectral domain optical coherence tomography (p \\\u003C 0.05)\n* progression of visual field defects\n* visually significant cataract and indication to reduce IOP or glaucoma medication burden\n\nExclusion Criteria:\n\n* clinical diagnosis of neovascular glaucoma, angle-closure glaucoma, uveitic glaucoma, neovascular glaucoma\n* prior glaucoma surgery\n* preexisting conditions affecting the episcleral venous pressure including Grave's ophthalmopathy, Sturge-Weber syndrome, Arteriovenous fistulas (carotid-cavernous fistula)",{"count":271,"type":20},55,[23],"The purpose of this study is to perform trabeculopuncture a test to determine the distal outflow tract function to predict the success of ab interno trabeculectomy.",[26,63],[276,277,26],"Ab Interno Trabeculectomy","Trabeculopuncture","2025-04-02",{"date":280,"type":35},"2025-04-03",{"date":282,"type":35},"2023-06-13",{"date":284,"type":20},"2026-01-31",{"name":286,"class":80},"Wuerzburg University Hospital",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":295,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":21,"phases":298,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":314,"locationsCount":81},"100576986","phase-4-a-study-investigating-oral-semaglutide-in-people-with-open-angle-glaucoma-100576986","NCT06792422","A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma","Additive Benefits of Semaglutide for Open-AngLe Glaucoma - an Opportunity for Neuroprotection","ABSALON","Inclusion Criteria:\n\n* Ability to read and speak Danish\n* 45 years or older at the time of inclusion\n* Visual acuity equal to or above 0.5 in the study eye\n* Diagnosis of POAG with MD ≤ 16 dB with repeatable and reliable (false positive less than 15 %) VF loss measured by standard automated perimetry on at least one eye\n* Receiving IOP-lowering glaucoma treatment\n* Nerve fiber layer defects identified by OCT\n\nExclusion Criteria:\n\n* Diabetes or renal impairment\n* Medical history of significant eye disease (including ocular trauma) other than glaucoma\n* Ocular inflammation\u002Finfection within three months from inclusion\n* Intraocular surgery 3 months before inclusion\n* Smoker at the time of inclusion\n* Pregnant or breast-feeding\n* Females of childbearing potential who are not using adequate contraceptive, which includes the following: Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal, progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable; Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomised partner; Sexual abstinence\n* Subjects allergic to drug ingredients administered during the trial\n* Subjects with untreated severe systemic disease or malignancies\n* Previous history of pancreatitis\n* BMI \\\u003C 18.5\n* Subjects receiving treatment with: Dipeptidyl peptidase-4 inhibitors; Other GLP-1RAs; Insulin; Insulin analogues; Sulfonylurea; Systemic corticosteroids; Immunosuppressants","45 Years",{"count":297,"type":20},126,[92],"The aim of this clinical trial is to investigate whether oral semaglutide can be used to treat open-angle glaucoma. The main question it aims to answer is: Does oral semaglutide safely improve inner retinal function in patients with open-angle glaucoma as measured by the photopic negative response of the electroretinogram.\n\nResearchers will compare oral semaglutide to a placebo (a look-alike substance that contains no drug).\n\nParticipants will:\n\n* Take semaglutide or a placebo every day for 6 months.\n* Visit the clinic 5 times in total for tests and interviews: At baseline (the first day they are included in the study), after 1 month, after 2 months, after 3 months, and after 6 months (the last day they are included in the study).",[301,151,123],"Primary Open Angle Glaucoma (POAG)",[123,303,304,60,305,306,307],"Semaglutide","Rybelsus","GLP-1RA","Photopic Negative Response","GLP-1","2025-01-20",{"date":310,"type":35},"2025-01-24",{"date":312,"type":20},"2025-01",{"date":39,"type":20},{"name":315,"class":80},"Glostrup University Hospital, Copenhagen",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":81},"100563288","mims-retrospective-chart-review-100563288","NCT06614218","MIMS® Retrospective Chart Review","Minimally Invasive Micro Sclerostomy (MIMS®) Retrospective Chart Review","Inclusion Criteria:\n\n1. Eye treated with MIMS® Device as a standalone procedure\n2. MIMS® surgery was performed between 27 Sep 2023 and 30 April 2024","85 Years",{"count":325,"type":20},40,"This is a post-market clinical follow-up, retrospective chart review of MIMS® surgical procedures conducted during time period between Sep 2023 and May 2025.",[26],[329,330,331,332,129,333,124,334],"Polypharmacy","Intraocular Pressure","MIMS","Minimally Invasive Glaucoma Surgery","MTMT","Sclerostomy","2025-01-08",{"date":337,"type":35},"2025-01-10",{"date":339,"type":20},"2025-02-01",{"date":341,"type":20},"2026-01-01",{"name":343,"class":42},"Sanoculis Ltd",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":323,"enrollmentInfo":351,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":353,"conditions":354,"keywords":355,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":81},"100560493","inferonasal-mims-procedure-long-term-follow-up-extension-study-100560493","NCT06577857","Inferonasal MIMS® Procedure: Long-Term Follow-Up Extension Study","Minimally Invasive Micro Sclerostomy (MIMS®) Inferonasal Procedure: Long-Term Follow-Up Extension Study","Inclusion Criteria:\n\n1\\. Subject who underwent MIMS® inferonasal procedure, and surgery was performed not earlier than 24 months from enrollment",{"count":352,"type":20},53,"A long-term (24 and 30 months) follow-up extension, prospective, non-interventional, open label study for data collection from subjects who underwent prior MIMS® inferonasal surgery, in continuation of the previous clinical investigation with the MIMS® Device (MMS-EEU-5).",[26],[330,331,356,332,124,334,129],"Inferonasal","2024-09-24",{"date":359,"type":35},"2024-09-26",{"date":361,"type":35},"2022-11-04",{"date":363,"type":20},"2025-06-30",{"name":343,"class":42},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":323,"enrollmentInfo":372,"targetDuration":4,"studyType":21,"phases":374,"briefSummary":375,"conditions":376,"keywords":377,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":81},"100540200","safety-and-effectiveness-of-minimally-invasive-micro-sclerostomy-mims-to-reduce-intraocular-pressure-in-open-angle-glaucoma-which-is-not-controlled-despite-polypharmacy-100540200","NCT06313749","Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy","An Observer-Masked, Single-Arm, Multicenter Study to Evaluate the Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy","Inclusion Criteria:\n\n1. Male or female, ≥ 40 years to ≤ 85 years old\n2. Inadequately controlled primary open angle glaucoma with screening mean diurnal IOP of ≥ 21 mmHg and ≤ 40 mmHg despite polypharmacy\n3. Primary open angle glaucoma diagnosis based on:\n\n   1. Visual field mean deviation of -3dB or worse and\n   2. Glaucomatous optic nerve damage as evidenced by optic disc or retinal nerve fiber layer structural abnormalities documented on slit lamp stereo biomicroscopy or in stereo disc photos\n4. Presence of healthy, free, and mobile conjunctiva in the target quadrant\n5. Prior ab interno conjunctival-sparing glaucoma procedures were conducted more than 6 months prior to enrollment (e.g., iStent, Trabectome, gonioscopy-assisted transluminal trabeculectomy \\[GATT\\])\n6. Subject is able and willing to attend all scheduled follow-up exams\n7. Subject understands and signs the informed consent",{"count":373,"type":20},129,[23],"The goal of this clinical trial is to show non-inferiority of the MIMS® device\u002Fprocedure with Mitomycin-C, in terms of its surgical success rate, compared to trabeculectomy with Mitomycin-C in subjects diagnosed with primary open angle glaucoma, whose intraocular pressure is not controlled despite polypharmacy.\n\nEligible screened participants will undergo the MIMS® procedure and will be followed for a period of 12 months in this single-arm study. Investigators will compare the results of this study to the surgical success rate of traditional trabeculectomy with Mitomycin-C.",[60,26],[26,329,330,331,332,129,333],"2024-08-06",{"date":380,"type":35},"2024-08-07",{"date":382,"type":35},"2024-06-01",{"date":384,"type":20},"2025-12",{"name":343,"class":42},{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":21,"phases":395,"briefSummary":396,"conditions":397,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":403,"locationsCount":405},"100536626","phase-1-a-randomized-double-blind-parallel-group-two-arm-multiple-dose-multicenter-bioequivalence-study-with-clinical-endpoint-in-the-treatment-of-subjects-with-chronic-open-angle-glaucoma-or-ocular-hypertension-in-both-eyes-100536626","NCT06267274","A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes","A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes","Inclusion Criteria:\n\n1. Subjects willing and able to provide voluntary informed consent and to follow protocol requirements.\n2. Male or females aged ≥18 years.\n3. Subjects with chronic open-angle glaucoma or ocular hypertension in both eyes\n4. Subjects requiring treatment of both eyes and able to discontinue the use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.\n5. Adequate washout period prior to baseline of any ocular hypotensive medications as (to minimize potential risk to subjects due to intraocular pressure (IOP) elevations during the washout period, the Investigator may choose to substitute a parasympathomimetic or carbonic anhydrase inhibitor in place of a sympathomimetic, alpha-agonist, beta-adrenergic blocking agent, or prostaglandin; however, all the subjects must have discontinued their ocular hypotensive medications for the minimum washout period .\n6. Baseline (Day 0\u002Fhour 0) IOP ≥22 mm Hg and \\\u003C28 mm Hg in each eye, with difference between the IOP in left and right eyes not being more than 5 mm Hg\n7. Subjects' IOP is likely to be controlled with monotherapy as per the Investigator's discretion.\n8. Baseline best corrected visual acuity equivalent to Snellen acuity of 20\u002F100 or better in each eye, using a logarithmic visual acuity chart for testing at 10 feet (3 meters).\n9. Women of childbearing potential (defined as women physiologically capable of becoming pregnant unless they are using an effective method of contraception during the dosing of the study drug) practicing any of the following acceptable methods of contraception:\n\n   1. Oral or parenteral (injection, patch, or implant) hormonal contraception which has been continuously used for at least 1 month prior to first dose of study medication.\n   2. Intrauterine device (IUD) or intrauterine system (IUS)\n   3. Double barrier method of contraception (condom and occlusive cap or condom and spermicidal agent)\n   4. Male sterilization (at least 6 months prior to screening, should be the sole male partner for that subject)\n   5. Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation\n   6. Total abstinence; partial abstinence is not acceptable\n10. No history of addiction to any recreational drug or drug dependence or alcohol addiction\n\nExclusion Criteria:\n\n1. Female who are pregnant, lactating or planning a pregnancy.\n2. Subjects recently diagnosed with open-angle glaucoma or ocular hypertension and who are treatment naive.\n3. Contraindication or known hypersensitivity to Bimatoprost, related class of drugs, or any of the excipients of formulation.\n4. Current or history of severe hepatic or renal impairment.\n5. Current or history within 2 months prior to baseline of any other significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye (Note: stable myopia, strabismus, and cataracts as per the Investigator's discretion will be allowed provided that the other inclusion\u002Fexclusion criteria are met).\n6. Current corneal abnormalities that would prevent accurate IOP readings with Goldmann applanation tonometer.\n7. Functionally significant visual field loss in the Investigators' opinion.\n8. Subject with corneal grafts.\n9. Subject has contraindication to pupil dilation.\n10. Use at any time prior to baseline of an intraocular corticosteroid implant.\n11. Use of contact lens within 1 week prior to baseline.\n12. Use within 2 weeks prior to baseline of 1) a topical ophthalmic corticosteroid or 2) a topical corticosteroid.\n13. Use within 1 month prior to baseline of 1) a systemic corticosteroid or 2) high-dose salicylate therapy defined as 325 mg\u002Fday and taken on 3 consecutive days.\n14. Use within 6 months prior to baseline of intravitreal or subtenon injection of an ophthalmic corticosteroid.\n15. Underwent within 6 months prior to baseline any other intraocular surgery (e.g., cataract surgery).\n16. Underwent within 12 months prior to baseline any refractive surgery, filtering surgery, or laser surgery for IOP reduction (e.g., laser trabeculoplasty).\n17. Amblyopia - only one sighted eye.\n18. Subjects with a history of IOP previously uncontrolled on bimatoprost monotherapy.\n19. Significant ocular surface findings (e.g., hyperemia or irritation, mild or greater) in either eye found on gross macroscopic or slit lamp examination.\n20. Severe retinal disease or other severe ocular pathology, such as glaucomatous damage with a cup\u002Fdisk ratio greater than 0.8 (not including physiological cupping in the Investigators' opinion) or split fixation.\n21. Chronic use of any systemic medication that may affect IOP with less than 3 months stable dosing regimen (i.e., sympathomimetic agents, beta-adrenergic blocking agents, alpha-agonists, alpha-adrenergic blocking agents, calcium channel blockers, angiotensin-converting enzyme inhibitors, etc.)\n22. Central Corneal thickness (CCT) \\\u003C450 microns or \\>650 microns.\n23. Known history or presence of any uncontrolled systemic disease (e.g., cardiovascular disease, hypertension, diabetes mellitus, hepatic impairment, etc.)\n24. History of recurrent ocular seasonal allergies within the past 2 years.\n25. Any other medical condition or serious intercurrent illness that, in the Investigator's opinion, may make it undesirable for the subject to participate in the study and would limit adherence to the study requirements.\n26. Participation in any clinical study within 30 days before the first dose of the study drug.\n27. Subjects with known history of positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) infection.\n28. Subjects with positive urine pregnancy test.",{"count":394,"type":20},240,[56],"A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study",[119,95],"2024-08-05",{"date":378,"type":35},{"date":401,"type":35},"2024-04-01",{"date":224,"type":20},{"name":404,"class":42},"Amneal Pharmaceuticals, LLC",4,{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":21,"phases":415,"briefSummary":416,"conditions":417,"keywords":419,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":81},"100554388","phase-4-efficacy-of-nsaid-vs-steroid-nsaid-combo-post-selective-laser-trabeculoplasty-phase-4-single-center-rct-100554388","NCT06498440","Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT","Comparative Efficacy of NSAID and Steroid-NSAID Combination Following Selective Laser Trabeculoplasty: a Phase 4, Single-centre, Randomized Controlled Trial","CES-NSLT","Inclusion Criteria:\n\n* Adults aged 18 years and older.\n* Diagnosed with open-angle glaucoma.\n* Intraocular pressure (IOP) greater than 16 mmHg on at least two consecutive occasions separated by one month.\n* Visual acuity of 20\u002F200 or better in at least one eye.\n* Provided informed consent.\n\nExclusion Criteria:\n\n* Patients with any other ocular disorders or surgeries within the last six months.\n* Allergy or intolerance to ketorolac or fluorometholone.\n* Previous use of systemic ketorolac or fluorometholone in the past month.\n* Pregnancy or breastfeeding.\n* Patients who are unable to speak\u002Funderstand English.\n* Any condition that in the investigator's opinion would make participation not in the best interest of the patient or could prevent, limit, or confound the protocol-specified assessments.",{"count":297,"type":20},[92],"This clinical trial, led by Dr. Enitan A. Sogbesan at the Hamilton Regional Eye Clinic, St. Joseph's Healthcare Hamilton, aims to compare the efficacy and safety of non-steroidal anti-inflammatory drug (NSAID) ketorolac alone versus a combination of ketorolac and the corticosteroid fluorometholone, and a control group receiving no postoperative treatment. The trial will evaluate these treatment strategies following Selective Laser Trabeculoplasty (SLT) in patients with open-angle glaucoma. The primary objective is to determine the most effective postoperative management strategy to reduce inflammation, improve patient comfort, and control intraocular pressure (IOP). Participants will be randomly assigned to one of the three groups, with follow-up visits scheduled at 1 hour, 1 week, 1 month, 3 months, 6 months, and 1 year post-SLT. The study's findings aim to guide clinicians in optimizing postoperative care for better patient outcomes.",[26,95,418],"Postoperative Inflammation",[420,421,422,423,424,425,426,427,428,429],"Selective Laser Trabeculoplasty (SLT)","Non-steroidal anti-inflammatory drugs (NSAIDs)","Ketorolac","Fluorometholone","Postoperative care","Intraocular pressure (IOP)","Visual acuity","Glaucoma treatment","Ophthalmology","Randomized controlled trial (RCT)","2024-07-05",{"date":432,"type":35},"2024-07-12",{"date":434,"type":20},"2024-09-01",{"date":436,"type":20},"2025-07-01",{"name":438,"class":80},"St. Joseph's Healthcare Hamilton",{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":446,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":4},"100551099","the-a-d-a-g-i-o-study-100551099","NCT06455683","The A D A G I O Study","The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients With Glaucoma or Ocular Hypertension","Inclusion Criteria:\n\n* Males or females between the ages of 18 and 90 (inclusive).\n* Able to understand the study and give informed consent.\n* Willing, able and available to participate in the study. If Flurophotometer test required must not have had prior cataract surgery.\n* Diagnosis of glaucoma or OHT which requires glaucoma surgery (trans-trabecular meshwork surgery with or without an implant, trans-scleral surgery with or without implant, ciliary body treatment, suprachoroidal surgery with or without implant, external non-incisional treatment). (Defined as primary or secondary glaucoma; all types of secondary glaucoma may be included. Glaucoma will be diagnosed based on abnormal visual field testing and corresponding disc changes once seen by a glaucoma specialist.)\n* It is judged clinically safe for the patient to undergo treatment washout (stop taking glaucoma drops).\n\nExclusion Criteria:\n\n* Diagnostic criteria for inclusion not met.\n* Allergy to fluorescein.\n* It is judged as not clinically safe or patient is not willing to undergo treatment washout (stop taking glaucoma drops).\n* Current use of any investigational drug or device or current participation in an interventional clinical trial\u002Fstudy.\n* Participants in the study must be able to understand English to complete some of the tests so those who might not adequately understand written information or verbal explanations in English will not be included",{"count":447,"type":20},150,"This study aims to investigate the effect of different types of glaucoma surgery on aqueous dynamics parameters (IOP, aqueous flow rate, trabecular outflow facility and uveoscleral outflow) in patients with uncontrolled open angle glaucoma or ocular hypertension (OHT)",[26,95],"2024-06-07",{"date":452,"type":35},"2024-06-12",{"date":454,"type":20},"2024-06",{"date":456,"type":20},"2029-06",{"name":458,"class":80},"Guy's and St Thomas' NHS Foundation Trust"]